How Bayer Makes Decisions to Develop New Drugs - In Bayer Biological Products' first decision-analysis project, its strategic-planning department evaluated a new blood-clot-busting drug.
|Year of Publication:||
|Contributors:||Stonebraker, Jeffrey S.|
|Type of Publication:||Article|
|Title record from database:|| OLC-SSG Economic Sciences|
|Availability:||More access options|
|More options (other):|
|Description not available.|
Saved in bookmark lists
Similar items by author
ARTICLES - New York Power Authority Uses Decision An attempt to minimize damage to small fish Analysis to Schedule Refueling of Its Indian and fish eggs in scheduling power plant Point 3 Nuclear Power Plant shutdowns.
By: Dunning, Dennis J. Published: (2001)
NC State's Supply Chain Resource Cooperative Educates in the Real World
By: Handfield, Robert B. Published: (2011)
OR Practice-Modeling Potential Demand for Supply-Constrained Drugs: A New Hemophilia Drug at Bayer Biological Products
By: Stonebraker, Jeffrey S. Published: (2009)